Formulation of Stable Nanoliposomes of Docetaxel: Design, Optimization, and in-vitro Characterizatio

Background: Liposomes have a number of advantages over traditional dosage forms, including enhanced bioavailability, the capacity to release drugs at a slower and more consistent rate, and precise drug release. The FDA has approved docetaxel to treat locally advanced or metastatic breast cancer, head and neck cancer, and gastric cancer. Because docetaxel is a BCS Class 4 medication, its efficacy can be enhanced by using a liposomal formulation.

The goal of this study was to create a Docetaxel-loaded liposomal formulation.

Materials and Methods: Formulation batches were designed on the basis of solvent, lipid to cholesterol ratio, lipid to release modifier ratio, hydration temperature and various physicochemical and morphological properties of formulation were examined. The zeta potential, particle size determination, pH, stability, determination of encapsulation efficacy, morphology of formulation and in-vitro drug release were investigated.

The zeta potentials of FD5 and FD9 were discovered to be -12.6 to -12.9 mV and -10.6 to -11.9 mV, respectively. Batch FD5 and FD9 formulations had entrapment efficiencies of 83.20 percent and 85.22 percent, respectively. When FD5 and FD9 batches were compared, it was discovered that FD9 batch is better in every way than FD5. The FD9 formulation batch has a particle size of 105 nm, a zeta potential of -10.6 to -11.9 mV, a drug entrapment efficiency of 85.22 percent, a formulation assay of 99.56 percent, and a drug release time of up to 13 hours.

Conclusion: The Liposome formulation was successfully created and tested, according to the findings of the study.

Please see the link :- https://www.journaljpri.com/index.php/JPRI/article/view/30940